Zambon launches Xadago first in Germany, next in Switzerland
This article was originally published in Scrip
Zambon has launched Xadago (safinamide), an add-on therapy for treating idiopathic Parkinson's disease in its first market, Germany. It is the first new chemical entity to be approved for Parkinson's in 10 years.
You may also be interested in...
Italy’s privately held Zambon could pay up to €500m to bulk up its respiratory products pipeline, producing a nice return for Breath Therapeutics’ syndicate of European investors.
Meindert Boysen, head of NICE’s Centre For Health Technology Evaluation, shares advice for companies aiming to get their medicine to patients. His golden rules: engage in early advice and be more realistic about pricing.
In an exclusive interview with the Pink Sheet, senior NICE director Meindert Boysen reveals the best advice he ever received and how companies whose products are under review can improve their chances of success.